Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Physician Views: How do oncologists use companion diagnostics, what are the key challenges and which pharma companies are best at supporting them?

Physician Views: How do oncologists use companion diagnostics, what are the key challenges and which pharma companies are best at supporting them? - new market research report published


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-01-20 12:12:07 - Physician Views: How do oncologists use companion diagnostics, what are the key challenges and which pharma companies are best at supporting them? - a new market research report on companiesandmarkets.com

As exemplified by Roche´s R&D presentation last week (see Spotlight On: Roche´s R&D day – The key takeaways), the use of biomarkers to segment cancer patient populations – with the aim to both enhance the drug development process and the efficacy of resultant therapies – is set to play an integral role in how this disease area continues to develop.

There has already been notable commercial success with this approach and the use of companion diagnostics to identify which patients stand to benefit most from particular therapies - the best example probably being Roche´s own HER2-positive breast cancer treatment Herceptin.

The Swiss company plays a prominent role in this approach – Roche being the global leader in both the oncology drug and

 

 

diagnostic markets – but a biomarker approach to cancer drug development is now common place across the industry.

But what do physicians think of companion diagnostics and how they have evolved the treatment of cancer? The general sentiment suggests that they are a purely positive development, but do oncologists face particular challenges in using cancer treatments in conjunction with a companion diagnostic and what can be done to improve how these predictive tools can be used?

Reasons to Buy

This week´s Physician Views poll asks oncologists based in the US and 5EU markets:

- How many cancer patients they assess with a companion diagnostic prior to treatment?
- How the role of a companion diagnostic impacts their uptake/usage of an associated cancer product?
- What their biggest challenges are in using companion diagnostics and an associated cancer product?
- What pharmaceutical manufacturers could provide to improve and enhance the experience of using companion diagnostics?
- Which pharmaceutical companies provide the best support and most effective information regarding companion diagnostics and associated cancer treatments?

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com